Nautilus Biotechnology, Inc.
NAUTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nautilus Biotechnology, Inc. (NAUT) is listed under Biotechnology. With a market capitalization of $330.4M, it sits in small-cap territory. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Market Cap
$330.4M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-3.51
EPS (TTM)
$-0.47
EPS (Fwd)
$-0.74
ROE
-33.7%
ROA
-19.8%
Cash
$95.9M
Total Debt
$28.9M
Free CF
-$28.9M
52W Change
248.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $95.9M in cash comfortably exceeding the $28.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$28.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, NAUT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NAUT.